pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: Cell Therapy

Sep 22, 2023

Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing

Sep 11, 2023

Therapeutic Solutions International Reports Landmark Advancement in Stem Cell Therapy of Frontotemporal Dementia

Sep 5, 2023

Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy

Aug 24, 2023

Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes

Aug 16, 2023

Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis

Aug 16, 2023

Therapeutic Solutions International Subsidiary Allogen Biologics Inc. Successfully Manufactures JadiCell Master Cell Bank to Provide Cells for Right to Try Use and Phase III ARDS Clinical Trial

Aug 15, 2023

Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Aug 8, 2023

Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson's Disease

Jul 18, 2023

Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma

Jun 15, 2023

Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy

Jun 5, 2023

Vycellix Presents Proof-of-Concept Data for VY-UC Allogeneic Cell Therapy Platform at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting, Paris

May 30, 2023

Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference on Malignant Lymphoma, Lugano

May 25, 2023

Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure

May 24, 2023

Innovative Cellular Therapeutics (ICT) Presented Data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

May 22, 2023

Outpace Bio Expands Seattle Presence with Cell Therapy Research Hub and Collaborations with Leading Experts in Protein Design and Cancer Immunotherapy

May 19, 2023

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Metagenomi Presents New Data on Novel Gene Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems

May 18, 2023

Fractyl Health Unveils Groundbreaking Pre-Clinical Proof of Concept Results for its Rejuva Pancreatic Gene Therapy Platform for Metabolic Diseases at the American Society of Gene and Cell Therapy Congress

May 18, 2023

Be Biopharma Announces Oral Presentation on Precise Genome Engineering of Human B Cells to Express Diverse Therapeutic Proteins at American Society of Gene and Cell Therapy 26th Annual Meeting

May 18, 2023

Outpace Bio to Present New Data on OutSmart™ IL-2/15, a CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity, at the 2023 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 17, 2023

Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer

May 16, 2023

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Highlighting Optimization of Processes for Viral Vector Production

May 11, 2023

Forge Biologics Announces Eight Presentations at the Upcoming 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 11, 2023

Intergalactic Therapeutics to Present Preclinical Data Highlighting Potential of Its Non-Viral Gene Therapy Platform at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 11, 2023

Nanoscope Therapeutics Announces Presentations at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

May 10, 2023

Capsida Biotherapeutics to Present New Data Showing Increased Capsid Expression in CNS at American Society of Gene and Cell Therapy 26th Annual Meeting

May 9, 2023

Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva Pancreatic Gene Therapy Platform Program at the American Society of Gene and Cell Therapy Congress

May 9, 2023

Affini-T Therapeutics to Present Novel CRISPR Gene Editing Data from its Oncogenic Driver Program Targeting KRAS at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 9, 2023

Outpace Bio, a Leader in Protein Design for Cell Therapy, Announces Presentation at the 2023 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 8, 2023

Mammoth Biosciences to Present at the 2023 Annual Meeting of the American Society of Gene and Cell Therapy

May 3, 2023

Umoja Biopharma to Present New Data at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 2, 2023

Be Biopharma Announces First Scientific Disclosures and New Preclinical Data Supporting the Advancement of B Cell Medicines at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 2, 2023

Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 2, 2023

Kriya to Present 10 Abstracts at the 2023 American Society of Gene and Cell Therapy Annual Meeting

May 2, 2023

Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

May 2, 2023

Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 2, 2023

Arbor Biotechnologies Announces Presentations at the 2023 Annual Meeting of the American Society of Gene and Cell Therapy

May 2, 2023

LEXEO Therapeutics Announces Data Presentations at the 26th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 2, 2023

NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

Apr 26, 2023

Tevogen Bio CSO to Discuss Investigational T Cell Therapy at NOLA Conference Focused on Long COVID and COVID-Related Cancer Risk, Alongside Leading Oncology Experts

Apr 25, 2023

Turn Biotechnologies to Discuss Promise of Epigenetic Reprogramming in CAR-T Cell Therapy at World Oncology Cell Therapy Congress

Apr 24, 2023

Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 20, 2023

Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy

Apr 17, 2023

EXUMA Biotech Presents Early Clinical and Translational Findings from Solid Tumor Cell Therapy and In Vivo CAR Engineering Research at the AACR Annual Meeting 2023

Apr 14, 2023

ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable Cell Therapy Progress

Apr 13, 2023

Turn Biotechnologies Sharpens Immunology Focus by Adding Two Cell Therapy Specialists to its Medical Advisory Board

Apr 11, 2023

Sonoma Biotherapeutics Appoints Leaders in Cell Therapy and Immunology to Scientific Advisory Board

Apr 3, 2023

Therapeutic Solutions International Spin Off Campbell Neurosciences Announces Novel Mechanistic Data on CampbellCell Stem Cell Therapy for Schizophrenia

Mar 27, 2023

Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors

Mar 23, 2023

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

Mar 6, 2023

Immunomic Therapeutics Announces Presentation on Manufacturing Cell Therapies at Supply Chain and Logistics for Cell Therapy Summit 2023

Feb 14, 2023

Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy

Feb 1, 2023

Kevin D’Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer

Jan 23, 2023

Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform

Jan 4, 2023

Tevogen Bio Appoints Cell Therapy Expert Dr. Dolores Grosso as Global Clinical Development Lead to Accommodate Its Expanding Portfolio

Jan 3, 2023

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

Dec 20, 2022

Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer

Dec 14, 2022

Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis

Dec 12, 2022

Orca Bio Presents Encouraging Interim Clinical Data on Orca-Q in Haploidentical Allogeneic Hematopoietic Stem Cell Transplants at 64th ASH Annual Meeting

Dec 11, 2022

Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting

Dec 11, 2022

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event

Dec 10, 2022

Orca Bio Presents Data Demonstrating its Lead Investigational High-Precision Cell Therapy Orca-T Significantly Improved Relapse-Free Survival at 64th ASH Annual Meeting

Dec 8, 2022

Federation Bio Administers First Dose in Phase 1 Clinical Trial Evaluating Investigational Bacterial Cell Therapy

Dec 7, 2022

Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options

Dec 5, 2022

Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting

Nov 28, 2022

Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform

Nov 22, 2022

Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID

Nov 21, 2022

Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data

Nov 18, 2022

EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia

Nov 15, 2022

ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T's T Cell Therapy Programs Targeting Core Oncogenic Drivers

Nov 15, 2022

ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers

Nov 10, 2022

Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022

Nov 10, 2022

Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting

Nov 8, 2022

Notch Therapeutics Enhances Cell Therapy Expertise with Updates to Scientific Advisory Board

Nov 8, 2022

ExCellThera announces 100th patient treated with UM171-expanded cell therapy

Nov 4, 2022

NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson’s Disease

Nov 4, 2022

ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting

Nov 3, 2022

Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition

Nov 3, 2022

Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101

Nov 3, 2022

Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting

Nov 2, 2022

PACT Pharma to Present New Data Highlighting First-of-its-Kind Personalized Neoantigen TCR T Cell Therapy Platform at SITC 2022

Oct 27, 2022

Aurion Biotech Wins Prestigious Prix Galien Startup Award

Oct 19, 2022

Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco

Oct 18, 2022

Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS T Cell Therapy for Neuroblastoma

Oct 17, 2022

NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors

Oct 11, 2022

Two-Year Clinical Data for DiscGenics's Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented at NASS 2022

Oct 5, 2022

LEXEO Therapeutics to Present New Clinical Data from its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer’s Disease at the 29th European Society of Gene and Cell Therapy Annual Meeting

Oct 3, 2022

Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection

Sep 26, 2022

Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for Duchenne Muscular Dystrophy Demonstrates Clinically Significant Functional and Biomarker Improvements

Sep 20, 2022

Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of Solid Tumors

Sep 20, 2022

Center for Breakthrough Medicines (CBM) and jCyte Announce Strategic Partnership to Manufacture jCyte's Innovative Cell Therapy for Treatment of Retinal Degenerative Diseases USA - English USA - English

Sep 14, 2022

Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering

Sep 6, 2022

Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress

Sep 2, 2022

Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products

Aug 25, 2022

Wugen Appoints Natalie Mount, Ph.D., as Chair of the Board of Directors

Aug 24, 2022

Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy RandD and Manufacturing Center

Aug 1, 2022

Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients

Jul 26, 2022

Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer

Jun 29, 2022

ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

Jun 21, 2022

NKGen Biotech to Participate in Truist Securities Cell Therapy Symposium

Jun 13, 2022

Tessa Therapeutics to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS Cell Therapy Conference 2022

Jun 12, 2022

IASO Bio and Innovent Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022

Jun 12, 2022

Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022

Jun 7, 2022

Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients

Jun 7, 2022

Immunomic Therapeutics Appoints Vice President, Cell Therapy

May 23, 2022

Elicio Therapeutics Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy Enhances Anti-Tumor Function and Eradicates Solid Tumors

May 19, 2022

Avenge Bio Presents Preclinical Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2022

Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans

May 18, 2022

Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 17, 2022

Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 17, 2022

Innovative Cellular Therapeutics (ICT) to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

May 17, 2022

Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene and Cell Therapy 25th Annual Meeting

May 16, 2022

PACT Pharma Highlights Capabilities and Versatility of Novel Non-Viral Gene Editing Technology in Presentation at American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

May 16, 2022

Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)

May 16, 2022

Affinia Therapeutics Presents New Data at American Society of Gene and Cell Therapy Annual Meeting

May 16, 2022

Factor Bioscience to Deliver Four Presentations at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

May 9, 2022

Ambys Medicines to Present New Data on Liver Cell Replacement Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 8, 2022

Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting 2022

May 5, 2022

CODA Biotherapeutics Announces Preclinical Data From Epilepsy Program to be Presented at American Society of Gene and Cell Therapy 25th Annual Meeting

May 5, 2022

Metagenomi to Present New Preclinical Data at the Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 5, 2022

NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

May 4, 2022

ElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 3, 2022

LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 3, 2022

Affini-T Therapeutics’ KRAS TCR T Cell Therapy Program to be Presented at the Annual Meeting of the American Society of Gene and Cell Therapy

May 3, 2022

Ring Therapeutics Announces Two Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 2, 2022

Forge Biologics Announces 7 Presentations at the Upcoming Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 2, 2022

Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell™ Universal Donor Stem Cell Drug

May 2, 2022

Arbor Biotechnologies Announces Presentations at 2022 Annual Meeting of the American Society of Gene and Cell Therapy

May 2, 2022

Umoja Biopharma to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting

Apr 29, 2022

Elicio Therapeutics Presents Preclinical Data on the AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy for Solid Tumors at the 2022 Keystone Symposia: Emerging Cellular Therapies

Apr 29, 2022

Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights

Apr 27, 2022

Catamaran Bio Appoints Cherry Thomas, MD, as Chief Medical Officer

Apr 27, 2022

Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform

Apr 25, 2022

Orca Bio Presents Positive Data Reinforcing Clinical Profile and Manufacturing Reliability of Orca-T at 2022 Transplantation and Cellular Therapy ASTCT and CIBMTR Tandem Meetings

Apr 21, 2022

Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses

Apr 19, 2022

SwanBio Therapeutics to Present Preclinical Data on Lead Candidate at American Society of Gene and Cell Therapy

Apr 18, 2022

Paul Laikind, PhD, Joins Stemson Therapeutics Board of Directors

Apr 14, 2022

Forge Biologics to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 13, 2022

ExCellThera announces new publication showing its ECT-001 cell therapy improves transplant access for all patients

Apr 13, 2022

Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A

Apr 8, 2022

Asher Bio to Unveil Two New Immunotherapy Programs, a CD8+ T Cell Targeted IL-21 and a Cis-Targeted IL-2 for Cell Therapy Augmentation, at AACR Annual Meeting

Apr 8, 2022

Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting

Apr 8, 2022

Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT‑179, a HER2-targeted Allogeneic CAR-NK Cell Therapy

Apr 7, 2022

Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for the Treatment of Duchene Muscular Dystrophy Shows Safety and Functional Improvements

Apr 6, 2022

Abata Announces Formation of Advisory Board Comprised of Leading Industry Experts in Treg Biology, Cell Therapy and Corporate Development

Apr 6, 2022

Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US

Apr 1, 2022

Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy

Mar 22, 2022

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

Mar 15, 2022

Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL

Mar 10, 2022

ExCellThera announces first patient treated in Phase I/II trial of ECT-001 cell therapy for pediatric patients with high risk blood cancer

Mar 8, 2022

Hope Biosciences’ Cell Therapy Shown Safe, Beneficial for Rheumatoid Arthritis

Mar 3, 2022

MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers

Mar 1, 2022

IASO Bio's Nanjing Manufacturing Facility Granted the Drug Manufacturing License for CAR-T Cell Therapy Products

Feb 25, 2022

DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease

Feb 14, 2022

Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Preclinical Safety and Efficacy Data Using CampbellCell™ for Treatment of Schizophrenia

Feb 13, 2022

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent

Feb 13, 2022

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio

Feb 10, 2022

Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer

Feb 8, 2022

Morphocell Technologies Announces a New Stem Cell Process That May Pave Way for Liver Cell Therapy and Drug Development

Feb 8, 2022

EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs

Feb 3, 2022

Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients

Feb 1, 2022

Feb 1, 2022

Stemson Therapeutics Secures 15M Series A Funding to Cure Hair Loss

Feb 1, 2022

Stemson Therapeutics Announces Additions To Its Scientific Advisory Board

Jan 12, 2022

Tevogen Bio™ Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Jan 10, 2022

ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors

Jan 10, 2022

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

Jan 10, 2022

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct USA - English USA - English

Jan 4, 2022

Dystrogen Therapeutics Announces First in Man Dosing of Novel Chimeric Cell Therapy for Duchenne Muscular Dystrophy and Reports 6-week Clinical Outcomes

Dec 30, 2021

Therapeutic Solutions International Successfully Treats “No Option” Patients with its JadiCell™ Stem Cell Therapy While Advancing Preparations for Phase III COVID-19 Clinical Trial

Dec 29, 2021

Tevogen Bio Reinforces IP Portfolio With Additional US Patent for Its Investigational T Cell Therapy for Treatment of COVID-19

Dec 15, 2021

Turnstone Biologics Expands Scientific Advisory Board with Appointments of Dr. James Mulé and Dr. Eric Tran

Dec 14, 2021

CytoImmune Appoints Distinguished Cell Therapy and Chemistry, Manufacturing and Controls Expert as Puerto Rico-Based Chief Operating Officer

Dec 13, 2021

Catamaran Bio Presents Preclinical Data Supporting CAT-248, an Off-the-Shelf CD70-Targeted CAR-NK Cell Therapy for the Treatment of CD70-Expressing Cancers

Dec 12, 2021

Wugen Presents New Preclinical Data Supporting the Safety and Efficacy of WU-CART-007 for T-Cell Malignancies at the 63rd Annual Society of Hematology (ASH) Annual Meeting

Dec 11, 2021

Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)

Dec 11, 2021

Positive Clinical Results from More than 100 Patients Treated with Orca Bio’s Lead Investigational High Precision Cell Therapy Presented at 63rd ASH Annual Meeting

Dec 3, 2021

Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society

Dec 1, 2021

Cellevolve Announces Global Partnership with QIMR Berghofer Medical Research Institute to Advance Novel Off-the Shelf T-cell Therapy in the First Randomized Cell Therapy Trial for Progressive Multifocal Leukoencephalopathy (PML)

Nov 29, 2021

Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform

Nov 18, 2021

Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing

Nov 16, 2021

Metagenomi to Present at CRISPR 2.0 Conference Highlighting the Company’s Novel Base Editor, Novel CRISPR Systems, and Metagenomics Discovery Engine

Nov 12, 2021

Carisma Therapeutics Presents Data from Phase I Clinical Trial of CT-0508, A HER2 Targeted CAR-Macrophage

Nov 12, 2021

Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Nov 10, 2021

IASO Biotherapeutics and Innovent Biologics to Present New BCMA CAR-T Cell Therapy Data in Oral Presentation at ASH 2021

Nov 9, 2021

Strand Therapeutics Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma

Nov 9, 2021

MiNK Therapeutics Presents New Preclinical and Clinical Data on iNKT Cell Therapy Programs at SITC 2021

Nov 8, 2021

Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021

Nov 8, 2021

ClearPoint Neuro Congratulates Neurona Therapeutics on IND Clearance for Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients

Nov 4, 2021

Catamaran Bio Announces Lead CAR-NK Cell Therapy Programs and Upcoming Data Presentation at ASH 2021

Nov 4, 2021

PlateletBio Completes $75.5M Series B Financing

Nov 4, 2021

Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients

Nov 3, 2021

Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Therapy Data at 2021 ASH Annual Meeting

Oct 27, 2021

Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy

Oct 19, 2021

Quell Therapeutics Presents New Data Demonstrating the Ability of its Proprietary Phenotype Lock Technology to Enhance the Safety, Stability and Efficacy of Engineered Treg Therapies

Oct 15, 2021

Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a Novel TCR-Based T Cell Therapy Company and TIO Bioventures Portfolio Company

Sep 29, 2021

XNK Therapeutics targets broader pipeline opportunities for its NK cell therapy

Sep 27, 2021

Ambys Medicines Announces Presentation on Novel Liver Cell Therapy Platform for Severe Liver Diseases, and Opening of its cGMP Cell Therapy Manufacturing Facility

Sep 27, 2021

ASC Therapeutics Appoints Gene and Cell Therapy Manufacturing Veteran Gary Potter to lead Global Operations

Sep 24, 2021

Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy

Sep 14, 2021

Aurion Biotech Announces Strategic Investments in Manufacturing

Sep 13, 2021

ViaCyte Appoints Stem Cell Therapy Expert Dr. Timothy Kieffer as Chief Scientific Officer

Sep 13, 2021

Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline

Sep 9, 2021

Tevogen Bio Reaches Major Milestone in Commercial Manufacturing Readiness by Completing the Technology Transfer of its Investigational COVID-19 T Cell Therapy

Sep 8, 2021

Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

Sep 8, 2021

EdiGene Announces Clinical Sites Activation and First Patient Enrolled in Multicenter Phase I Clinical Trial of its Investigational Gene-editing Hematopoietic Stem Cell Therapy ET-01 for Patients with Transfusion Dependent β-thalassemia

Aug 31, 2021

Tevogen Bio to Initiate Clinical Trial of its Investigational T Cell Therapy for COVID-19 at Thomas Jefferson University

Aug 12, 2021

Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply

Aug 11, 2021

Be Bio Appoints Leading Cell and Gene Therapy Executives, Krishnan Viswanadhan as President and Chief Operating Officer, and Brad Hartman as Chief People Officer

Aug 4, 2021

Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases

Jul 25, 2021

Aurion Biotech Announces IOTA Cell Therapy Trial

Jul 22, 2021

Quell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer

Jul 21, 2021

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS T Cell Therapy in Liver Cancer

Jul 15, 2021

GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership

Jul 13, 2021

Aurion Biotech Appoints Professor Shigeru Kinoshita, MD, PhD, to Its Medical Advisory Board

Jul 12, 2021

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Jul 12, 2021

Tevogen Bio Announces FDA Clearance of Investigational New Drug (IND) Application For its Cytotoxic T Cell Therapy for COVID-19

Jul 7, 2021

Inceptor Bio Launches FastBack Bio, Its First Portfolio Company Developing A Novel CAR-T Platform That Targets Difficult-To-Treat Cancers

Jul 6, 2021

First Patient Dosed with Gadeta's gamma delta TCR Cell Therapy

Jun 23, 2021

Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells to Treat Serious Autoimmune and Inflammatory Diseases

Jun 23, 2021

Tessa Therapeutics Announces Collaboration with A*STAR’s Institute of Molecular and Cell Biology to Form Cell Therapy Laboratory

Jun 16, 2021

Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)

Jun 14, 2021

Inceptor Bio Launches Next-Generation CAR-T, CAR-M, and NK/NKT Platform Focused on Advancing Cell and Gene Therapies to Cure Difficult-To-Treat Cancers

Jun 11, 2021

Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure

Jun 4, 2021

Worldwide CAR-T Cell Therapy Industry - Featuring Aleta BioTherapeutics, Atara Biotherapeutics and BioNTech Among Others

May 20, 2021

Medeor Therapeutics to Provide Interim Results of Phase 3 Mercury Study of MDR-101 Cell Therapy in Living Donor Kidney Transplants During Rapid Fire Oral Presentation at ATC Virtual Congress

May 19, 2021

Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy

May 13, 2021

Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting

May 13, 2021

Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India

May 12, 2021

ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement

May 11, 2021

ViaCyte To Participate In World Medical Innovation Forum Panel On Future Of Cell Therapy For Type 1 Diabetes

May 11, 2021

Dyno Therapeutics Presents State-of-the-Art Applications of Machine Learning to Design Improved AAV Capsids for a Broad Range of Gene Therapies at American Society of Gene and Cell Therapy Conference

May 11, 2021

Catamaran Bio’s Scientific Founder Leads Pivotal Advancements in Non-viral Engineering of CAR-NK Cells Using Novel Transposon Technology

May 11, 2021

Factor Bioscience to Deliver Six Digital Presentations at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting

May 7, 2021

Tessa Therapeutics’ Allogeneic, “Off-the-Shelf” CD30 Cell Therapy to be Featured in Podium Presentation at the ASGCT 24th Annual Meeting

May 5, 2021

Locanabio Announces Upcoming Preclinical Data Presentations at American Society of Gene and Cell Therapy Annual Meeting

May 4, 2021

Shape Therapeutics Announces Presentations at the Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Apr 28, 2021

CARISMA Therapeutics to Present Data at The American Society of Gene and Cell Therapy 24th Annual Meeting

Apr 28, 2021

LEXEO Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy (ASGCT) 2021 Virtual Annual Meeting

Apr 28, 2021

M6P Therapeutics Announces Presentation at the Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Apr 27, 2021

Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting

Apr 27, 2021

Dyno Therapeutics Announces Presentations at 2021 American Society of Gene and Cell Therapy Annual Meeting

Apr 27, 2021

Metagenomi to Present New Preclinical Data from Novel Gene Editing Programs at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Apr 27, 2021

Aruvant Announces Oral Data Presentation at American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting

Apr 27, 2021

DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone

Apr 26, 2021

CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages

Apr 19, 2021

Porton Biologics Announces Closing Series-A Financing to Drive Commercial Production of Gene and Cell Therapy

Apr 15, 2021

CERo Therapeutics Expands Leadership Team with Experts in Cell Therapy Development

Apr 13, 2021

Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas

Apr 12, 2021

Tevogen Bio to Present Preclinical Data of TVGN-489, its Investigational Allogeneic Cytotoxic T Cell Therapy for COVID-19, at the 2021 Annual Meeting of American Association of Immunologists

Apr 6, 2021

Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma

Mar 31, 2021

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

Mar 18, 2021

ONK Therapeutics Strengthens its Cell Therapy Manufacturing Process with License for EBV-LCL Feeder Cell Line from NIH to Enhance NK Cell Expansion

Mar 18, 2021

Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme

Mar 15, 2021

Tevogen Bio Announces Partnership With BioCentriq, New Jersey Innovation Institute’s Pioneering Cell and Gene Therapy Center, to Enhance Tevogen’s Development Capacity of Its Proprietary Targeted T Cell Therapy For COVID-19

Mar 10, 2021

Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

Mar 9, 2021

ImmunityBio and NantKwest Complete Merger

Mar 8, 2021

ArsenalBio Announces Appointment of John Schroer as Chief Financial Officer and Tim Sirichoke as Chief Technical Operations Officer

Mar 8, 2021

IONTAS and FairJourney Biologics Enter Antibody Discovery Agreement With Quell Therapeutics

Mar 3, 2021

Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline

Mar 3, 2021

Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline

Feb 24, 2021

Metagenomi Announces the Addition of Leading Immuno-oncology Clinical Research Experts to its Scientific Advisory Board

Feb 10, 2021

Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial

Feb 3, 2021

ViaCyte Announces Initiation of Phase 2 Study of Encapsulated Cell Therapy for Type 1 Diabetes Patients

Feb 3, 2021

Thermo Fisher Scientific and JW Therapeutics Announce CAR-T Partnership in China

Jan 25, 2021

TScan Therapeutics Announces $100 Million Series C Financing

Jan 25, 2021

Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19

Jan 21, 2021

Kuur Therapeutics Announces Interim Clinical Data Supporting CAR-NKT Cell Therapy Platform

Jan 20, 2021

Turnstone Biologics Acquires Novel Cell Therapy Platform

Jan 18, 2021

EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia by China National Medical Products Administration

Jan 15, 2021

Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products

Jan 11, 2021

Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid's Cell Therapy Programs

Jan 7, 2021

ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors

Jan 6, 2021

Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials

Dec 23, 2020

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers

Dec 23, 2020

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck To Develop Allogeneic Cell Therapy For Solid Tumor Cancers

Dec 21, 2020

ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company

Dec 17, 2020

ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline

Dec 11, 2020

ExCellThera receives Priority Medicines (PRIME) designation from European Medicines Agency for ECT-001 Cell Therapy

Dec 8, 2020

Cytovia Therapeutics announces plans to initiate in 2021 Clinical Development of Universal iPSC NK Cell Therapy for Hematological and Solid Tumors

Dec 8, 2020

Global Stem Cell Therapy Market (2020 to 2025) - Players Include Biotime, Sanbio and Bluerock Therapeutics - ResearchAndMarkets.com

Dec 7, 2020

Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma

Dec 7, 2020

Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell Lymphomas

Dec 6, 2020

CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 6, 2020

ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting

Dec 5, 2020

Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Multiple Myeloma at 2020 ASH Annual Meeting

Nov 23, 2020

ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing

Nov 23, 2020

Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf CAR-NK Cell Therapies to Treat Solid Tumors

Nov 20, 2020

CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December

Nov 19, 2020

Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020, a Novel Experimental Cell Therapy for Glioblastoma

Nov 12, 2020

Metagenomi Presents Findings on Three New CRISPR-associated Gene Editing Systems and their Ability to Edit T-Cell and NK-Cell Genomes for Use in Cell Therapy

Nov 5, 2020

Porton Biologics Launched Gene and Cell Therapy CDMO Platform to Rank Among the Top of Pharma Solutions Platforms

Nov 2, 2020

CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates

Nov 2, 2020

Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX

Oct 28, 2020

Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics Announce Investment to Advance Clinical Development of Natural Killer Cell Therapy

Oct 26, 2020

EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia Accepted for Review by China National Medical Products Administration

Oct 22, 2020

Vycellix CEO to Present its Universal Cell Program (VY-UC) for Off-the-Shelf NK Cell Therapy at Allogeneic Cell Therapies Summit

Oct 20, 2020

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

Oct 15, 2020

OncoPep Strengthens Pipeline with Addition of Multi-Tumor Antigen Adoptive T Cell Therapy

Oct 12, 2020

Kuur Therapeutics Announces Publication of Interim Phase 1 Data for CAR-NKT Cell Therapy KUR-501 in Nature Medicine

Oct 5, 2020

Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS T Cell Therapy in Hepatocellular Carcinoma

Oct 5, 2020

Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia

Oct 2, 2020

Arcellx to Present at Jefferies Virtual Cell Therapy Summit

Sep 29, 2020

Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October 2020

Sep 29, 2020

Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy

Sep 21, 2020

T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy

Sep 15, 2020

Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate

Sep 10, 2020

Immunomic Therapeutics Inc. Expands into South Korea

Sep 8, 2020

Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy

Aug 24, 2020

Arcellx Announces EvansMDS Grant Awarded for Collaboration with Johns Hopkins and University of Colorado Researchers to Support Development of Arcellx ARC-sparX Platform Candidate ACLX-002

Aug 6, 2020

Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma

Jul 8, 2020

FDA Approves Talaris Therapeutics’ IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma

Jul 8, 2020

APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

Jun 3, 2020

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

Jun 3, 2020

Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy

Jun 2, 2020

NKMax America Receives FDA Clearance of IND for Phase I/2a Trial of their Natural Killer Cell Therapy (SNK01) in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced/Metastatic HER2- or EGFR- Expressing Cancers

May 26, 2020

ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes

May 14, 2020

Innovative Cellular Therapeutics Announces Acceptance of Abstract on its Novel CoupledCAR Technology for Treating Colorectal Cancer for Oral Presentation at the 23rd American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 12, 2020

Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference

May 12, 2020

Dyne Therapeutics Demonstrates FORCE™ Platform’s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy

May 12, 2020

Dyne Therapeutics Demonstrates FORCE Platform’s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy

May 11, 2020

Tenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene and Cell Therapy

May 11, 2020

Decibel Therapeutics to Present at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 7, 2020

Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement

May 7, 2020

Taysha Gene Therapies Announces Presentations Highlighting Programs and Platform Technologies at the 2020 Annual Meeting of the American Society of Gene and Cell Therapy

Apr 29, 2020

Arcellx to Present Preclinical Efficacy Data of the ARC-sparX Platform Technology at the 2020 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Apr 29, 2020

4D Molecular Therapeutics Announces Upcoming Oral and Poster Presentations at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

Apr 29, 2020

Innovative Cellular Therapeutics Announces Details of Two Abstracts on its Novel CoupledCAR Solid Tumor CAR-T Technology to be Presented Orally at the 23rd American Society of Gene and Cell Therapy Meeting

Apr 3, 2020

Gracell Announces China NMPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Mar 24, 2020

Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors

Mar 23, 2020

AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19

Mar 17, 2020

RoosterBio Partners with Senti Biosciences to Rapidly Translate Gene Circuit Cell Therapy into the Clinic

Mar 4, 2020

DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease

Feb 28, 2020

Arcellx Announces First Patient Treated with T Cell Therapy Utilizing the Company’s Novel Binding Domain

Feb 27, 2020

Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma

Feb 9, 2020

KSQ Therapeutics Announces Discovery of Gene Targets with Potential Activity Superior to PD-1 for Development of Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapies for Solid Tumors

Feb 6, 2020

Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases

Jan 29, 2020

Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection

Jan 22, 2020

Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy

Jan 9, 2020

Aspen Neuroscience Announces Board of Directors and Scientific Advisory Board

Dec 19, 2019

Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility in Singapore in 2020

Dec 12, 2019

Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease

Dec 9, 2019

Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual Meeting

Dec 4, 2019

MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ's Adoptive Cell Therapy Programs

Dec 4, 2019

Innovative Cellular Therapeutics Announces FDA Clearance of IND for its Dominant Negative PD-1 “Armored” Next Generation CAR-T Cell Therapy

Dec 3, 2019

KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs

Nov 22, 2019

Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

Nov 11, 2019

Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World’s First Stem Cell Therapy Trial using HepaStem™ in Acute-on-Chronic Liver Failure

Nov 6, 2019

Celularity to Present New Data at the ASH Annual Meeting on Novel Allogeneic, Off the Shelf, Placental Derived CAR T and NK Cell Therapy Programs

Oct 28, 2019

DiscGenics Announces U.S. Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review

Oct 23, 2019

Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients

Oct 18, 2019

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

Oct 15, 2019

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

Oct 3, 2019

Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Platform

Oct 1, 2019

Tmunity Announces Exclusive License and Research Collaboration with Children’s Hospital of Philadelphia to Advance GPC2 CAR-T Cell Therapy for Neuroblastoma

Oct 1, 2019

ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research Center

Sep 16, 2019

DiscGenics' U.S. Clinical Study of Cell Therapy for Disc Degeneration Passes Halfway Mark

Sep 9, 2019

Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy

Sep 9, 2019

NKMax America Announces New cGMP Manufacturing Facility for Production of SNK Cell Therapy

Aug 26, 2019

DiscGenics Receives FDA Fast Track Designation for Cell Therapy for Disc Degeneration

Aug 8, 2019

Bayer acquires BlueRock Therapeutics to build leading position in cell therapy

Aug 7, 2019

DiscGenics Announces First Patients Treated in Japanese Clinical Trial of Cell Therapy for Degenerative Disc Disease

Jul 1, 2019

Century Therapeutics Launches With USD 250M Financing for Induced Pluripotent Stem Cell (iPSC) Allogeneic Cell Therapy Platform

Jul 1, 2019

Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform

May 30, 2019

Cell Medica Collaborators, Baylor College of Medicine and Texas Children’s Hospital, Present Positive Early Patient Data From CAR-NKT Neuroblastoma Trial at American Society Of Gene and Cell Therapy 22nd Annual Meeting

May 25, 2019

SQZ Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting

May 18, 2019

Talaris Therapeutics, Inc. Announces Promising Phase 2 Data of Novel, Allogeneic Cell Therapy in Living Donor Kidney Transplant Recipients

May 18, 2019

Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development

May 17, 2019

Cell Medica Collaborator, Baylor College of Medicine, Showcasing Promise of CAR-NKT Therapies at American Society of Gene and Cell Therapy 22nd Annual Meeting

May 15, 2019

Akouos Announces New Data at the American Society of Gene and Cell Therapy 2019 Annual Meeting

May 9, 2019

Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

May 8, 2019

Semma Therapeutics Announces Publication in Nature Demonstrating Advancements in Regenerative Cell Therapy for Type 1 Diabetes

May 8, 2019

Innovative Cellular Therapeutics Announces Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 1, 2019

Cell Medica Collaborators, Baylor College of Medicine and Texas Children’s Hospital, Present Preclinical Data for an off-the-shelf CAR-NKT Therapy Platform at American Society of Gene & Cell Therapy 22nd Annual Meeting

May 1, 2019

Tmunity and UC San Francisco Announce Exclusive License and Research Collaboration to Advance TCR T Cell Therapies for Pediatric Cancers

May 1, 2019

Cell Medica Collaborators, Baylor College of Medicine and Texas Children’s Hospital, Present Preclinical Data for an off-the-shelf CAR-NKT Therapy Platform at American Society of Gene and Cell Therapy 22nd Annual Meeting

Apr 30, 2019

Cell Medica Collaborators, Baylor College of Medicine and Texas Children’s Hospital, Present Positive Early Patient Data From CAR-NKT Neuroblastoma Trial at American Society Of Gene & Cell Therapy 22nd Annual Meeting

Apr 30, 2019

Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy

Apr 29, 2019

Beam Therapeutics Presents Data on Multiplex Base Editing for Engineered CAR-T Cells at American Society of Gene and Cell Therapy 22nd Annual Meeting

Apr 23, 2019

Vivet Therapeutics Announces 2 Abstracts Accepted for Oral Presentation at 2019 American Society of Gene and Cell Therapy Annual Meeting

Apr 17, 2019

Cell Medica Collaborator, Baylor College of Medicine, Showcasing Promise of CAR-NKT Therapies at American Society of Gene & Cell Therapy 22nd Annual Meeting

Apr 15, 2019

Akouos Announces New Data at the American Society of Gene & Cell Therapy 2019 Annual Meeting

Apr 15, 2019

Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer

Apr 8, 2019

SanBio Announces SB623 Regenerative Cell Therapy for Traumatic Brain Injury Has Received Ministry of Health, Labour and Welfare (MHLW) Sakigake Designation

Apr 3, 2019

Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms

Mar 29, 2019

Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019

Mar 4, 2019

Celltex Therapeutics Corporation Signs Memorandum of Understanding (MOU) with Saudi Arabia; Expands Presence to Riyadh

Feb 27, 2019

First Clinical Results Evaluating Allogeneic, Off-The-Shelf, Placental-Derived Cells to be Presented by Celularity at 2019 AACR Annual Meeting

Feb 26, 2019

Cell Medica Awarded USD 8.7 Million CPRIT Grant to Accelerate CMD-502 Off-the-shelf CAR-NKT Cell Therapy into Clinical Development

Feb 14, 2019

Vor Biopharma Completes $42 Million Series A Financing Round to Advance Lead Cell Therapy Product Candidate for the Treatment of Acute Myeloid Leukemia

Jan 21, 2019

Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients

Jan 7, 2019

DiscGenics Announces that Cell Therapy IDCT has Passed the Initial Safety Review of its First-in-Human Clinical Trial for Degenerative Disc Disease

Dec 3, 2018

WindMIL Therapeutics Announces Preclinical Data Demonstrating Marrow-Infiltrating Lymphocytes’ Potential as CAR-Modified T Cell Therapy Platform

Nov 29, 2018

ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

Nov 22, 2018

Vineti™ to Partner With Tessa Therapeutics™ to Advance and Scale Cancer Immunotherapies World-Wide

Oct 23, 2018

Don Haut, PhD, Joins AskBio as Chief Business Officer

Oct 23, 2018

Gain Therapeutics Files Registration Statement with SEC for Proposed Initial Public Offering

Oct 23, 2018

Aerium Therapeutics launches to develop novel therapeutics against COVID-19 and future pandemic threats

Sep 25, 2018

Gore Strengthens Collaborative Relationship with ViaCyte by Investing Additional $10 Million

May 16, 2018

Agilis Biotherapeutics Conducts a Scientific Symposium for Education and Awareness of AADC Deficiency at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 14, 2018

Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

May 14, 2018

Agilis Biotherapeutics Announces Data Presentations on AADC Deficiency at the American Society of Gene and Cell Therapy 2018 Annual Meeting

May 14, 2018

Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Mar 19, 2018

MaSTherCell Appointed as Process Development and Manufacturing Partner for Zelluna Immunotherapy’s TCR Adoptive Cell Therapy Platform

Jan 25, 2018

Rexgenero Treats First Patient in its Phase III Programme with Lead Product REX-001, a Novel Cell Therapy for the Treatment of Critical Limb Ischemia (CLI)

Nov 30, 2017

Semma Therapeutics Raises $114 Million Series B Financing

Nov 1, 2017

DiscGenics Joins MedCision’s ThawSTAR Early Adopter Program for Cell Therapy Clinical Trials

Oct 5, 2017

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Sep 28, 2017

Nohla Therapeutics Awarded $6.9 Million Grant from the California Institute of Regenerative Medicine to Further Develop NLA101 Cell Therapy for the Treatment of Patients with Acute Myeloid Leukemia

Sep 6, 2017

Longeveron Initiates Phase 2b Stem Cell Therapy Trial to Treat Aging Frailty

Jun 27, 2017

BlueRock Therapeutics Announces Key Members of Executive Team

Jun 20, 2017

Cell Medica Acquires WT1 Cancer Immunotherapy from Cell and Gene Therapy Catapult

May 22, 2017

ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes

May 21, 2017

Promethera Biosciences Presents Preclinical Data on Novel H2Stem Cell Therapy at EASL International Liver Congress

Mar 28, 2017

Nohla Therapeutics Announces Collaboration with University of California, Davis to Optimize Manufacturing Process and Supply Cell Therapy Product for Clinical Trials

Dec 12, 2016

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

May 26, 2016

Caladrius Biosciences Licenses Cell Therapy Technology for Ovarian Cancer and Subleases Irvine Facility to AiVita Biomedical

Sep 8, 2015

PCT, LLC, A Caladrius Company, to Manufacture EU-Compliant Cell Therapy Product for IRX Therapeutics, Inc. From Its New Jersey Facility

Sep 2, 2015

Precision BioSciences Announces Appointment of Gene Liau, Ph.D. and Bruce McCreedy, Ph.D. to Management Team

Mar 24, 2015

Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical Company

Mar 11, 2015

Cell Medica Collaborates with Cell Therapy Catapult to Help Bring Its New Treatment to NHS

Aug 8, 2014

ViaCyte, Inc. Raises $5.4 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product VC-01™ for Insulin-Dependent Diabetes

Apr 30, 2014

NeoStem's Subsidiary, Progenitor Cell Therapy Enters Into a Services Agreement With IRX Therapeutics, Inc.

Feb 14, 2014

SanBio Announces the First Public Presentation of Data from its On-going Human Clinical Trial of Cell Therapy for Chronic Stroke Disability

Feb 6, 2014

JDRF to Provide Additional Support for Upcoming Clinical Trial of ViaCyte's Encapsulated Cell Therapy for Type 1 Diabetes

Sep 26, 2013

Cell Medica opens a central European manufacturing facility in Berlin–Buch (Germany)

Jul 10, 2013

ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes

Jun 10, 2013

SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury

Feb 28, 2013

Discgenics Successfully Completes Pilot Efficacy Study of Injectable Discosphere™ Cell Therapy

Jan 31, 2013

ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

Jan 14, 2013

SanBio Announces Enrollment Of The Second Cohort Of Patients In Its Clinical Trial Of Stem Cell Therapy For Chronic Stroke

Sep 20, 2011

SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center

Apr 21, 2011

Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability

Nov 2, 2010

Argos Therapeutics to Present About the Implementation, Cost Effectiveness and Benefits of Automation for its Arcelis™ Immunotherapy at The Cell Therapy Industry Summit-2010

Oct 4, 2010

Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery